Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0JR9V
|
||||
| Former ID |
DIB009055
|
||||
| Drug Name |
JBP-1
|
||||
| Synonyms |
Trypsinogen/chymotrypsinogen/amylase (metastatic cancer), Propanc
|
||||
| Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Investigative | [1], [2] | ||
| Company |
Propanc Pty Ltd
|
||||
| Target and Pathway | |||||
| Target(s) | Chymotrypsin | Target Info | Modulator | [1], [2] | |
| Alpha-glucosidase | Target Info | Modulator | [1], [2] | ||
| Trypsin | Target Info | Modulator | [1], [2] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Pancreatic secretion | |||||
| Protein digestion and absorption | |||||
| Influenza A | |||||
| Reactome | Activation of Matrix Metalloproteinases | ||||
| Cobalamin (Cbl, vitamin B12) transport and metabolism | |||||
| WikiPathways | Activation of Matrix Metalloproteinases | ||||
| References | |||||
| REF 1 | US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. | ||||
| REF 2 | EP patent application no. 2490711, A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.